Skip to main content
Fig. 6 | Clinical Proteomics

Fig. 6

From: Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization

Fig. 6

Antibody-based confirmation of selected druggable enzymes markedly upregulated in cluster 1. (A) Western blots of 22 tumor samples and 2 controls (NAM pools). (B) Results of densitometric analyses of the blots. To normalize the signal intensity between the two blots, sample 4 was present on both membranes and used as an internal standard. Due to the heterogeneity of tumors, standard loading “housekeeping“ proteins, such as GAPDH, tubulin, actin, could not be used, as their antibody-detected levels varied significantly among the samples. Therefore, we used a Coomassie Brilliant Blue-stained gel as the loading control. SHMT2, serine hydroxymethyl transferase 2; ARG2, arginase 2 (mitochondrial); ATX, autotaxian alias ENPP2, ectonucleotide pyrophosphatase/phosphodiesterase family member 2

Back to article page

Clinical Proteomics

ISSN: 1559-0275